Tuberculosis and Respiratory Diseases最新文献_第10页

Progressive Pulmonary Fibrosis: Where Are We Now? 进行性肺纤维化：我们现在在哪里？

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-18 DOI: 10.4046/trd.2023.0119

Hyung Koo Kang, Jin Woo Song

{"title":"Progressive Pulmonary Fibrosis: Where Are We Now?","authors":"Hyung Koo Kang, Jin Woo Song","doi":"10.4046/trd.2023.0119","DOIUrl":"10.4046/trd.2023.0119","url":null,"abstract":"Interstitial lung diseases (ILDs) are a diverse collection of lung disorders sharing similar features, such as inflammation and fibrosis. The diagnosis and management of ILD require a multidisciplinary approach using clinical, radiological, and pathological evaluation. Progressive pulmonary fibrosis (PPF) is a distinct form of progressive and fibrotic disease, occurring in ILD cases other than in idiopathic pulmonary fibrosis (IPF). It is defined based on clinical symptoms, lung function, and chest imaging, regardless of the underlying condition. The progression to PPF must be monitored through a combination of pulmonary function tests (forced vital capacity [FVC] and diffusing capacity of the lung for carbon monoxide), an assessment of symptoms, and computed tomography scans, with regular follow-up. Although the precise mechanisms of PPF remain unclear, there is evidence of shared pathogenetic mechanisms with IPF, contributing to similar disease behavior and worse prognosis compared to non-PPF ILD. Pharmacological treatment of PPF includes immunomodulatory agents to reduce inflammation and the use of antifibrotics to target progressive fibrosis. Nintedanib, a known antifibrotic agent, was found to be effective in slowing IPF progression and reducing the annual rate of decline in FVC among patients with PPF compared to placebos. Nonpharmacological treatment, including pulmonary rehabilitation, supplemental oxygen therapy, and vaccination, also play important roles in the management of PPF, leading to comprehensive care for patients with ILD. Although there is currently no cure for PPF, there are treatments that can help slow the progression of the disease and improve quality of life.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"123-133"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment Outcomes of Fluoroquinolone-Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid. 对氟喹诺酮类药物耐药的 XDR 前期肺结核患者的治疗结果：对德拉马尼的影响

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-18 DOI: 10.4046/trd.2023.0188

Oki Nugraha Putra, Telly Purnamasari

引用次数: 0

Treatment Outcomes of Fluoroquinolone- Resistant Multidrug-Resistant Tuberculosis: An Implication for Delamanid - Authors' Reply. 对氟喹诺酮类药物产生耐药性的耐多药结核病的治疗结果：对地拉马尼的影响--作者回复。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-01-30 DOI: 10.4046/trd.2024.0010

Saerom Kim, Jeongha Mok

引用次数: 0

Oscillometry-Defined Small Airway Dysfunction in Patients with Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺病患者的振荡测定定义的小气道功能障碍。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-01-16 DOI: 10.4046/trd.2023.0139

Amit K Rath, Dibakar Sahu, Sajal De

{"title":"Oscillometry-Defined Small Airway Dysfunction in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Amit K Rath, Dibakar Sahu, Sajal De","doi":"10.4046/trd.2023.0139","DOIUrl":"10.4046/trd.2023.0139","url":null,"abstract":"Background: The prevalence of small airway dysfunction (SAD) in patients with chronic obstructive pulmonary disease (COPD) across different ethnicities is poorly understood. This study aimed to estimate the prevalence of SAD in stable COPD patients.Methods: We conducted a cross-sectional study of 196 consecutive stable COPD patients. We measured pre- and post-bronchodilator (BD) lung function and respiratory impedance. The severity of COPD and lung function abnormalities was graded in accordance with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. SAD was defined as either difference in whole-breath resistance at 5 and 19 Hz > upper limit of normal or respiratory system reactance at 5 Hz < lower limit of normal.Results: The cohort consisted of 95.9% men, with an average age of 66.3 years. The mean forced expiratory volume 1 second (FEV1) % predicted was 56.4%. The median COPD assessment test (CAT) scores were 14. The prevalence of post-BD SAD across the GOLD grades 1 to 4 was 14.3%, 51.1%, 91%, and 100%, respectively. The post-BD SAD and expiratory flow limitation at tidal breath (EFLT) were present in 62.8% (95% confidence interval [CI], 56.1 to 69.9) and 28.1% (95% CI, 21.9 to 34.2), respectively. COPD patients with SAD had higher CAT scores (15.5 vs. 12.8, p<0.01); poor lung function (FEV1% predicted 46.6% vs. 72.8%, p<0.01); lower diffusion capacity for CO (4.8 mmol/min/kPa vs. 5.6 mmol/min/kPa, p<0.01); hyperinflation (ratio of residual volume to total lung capacity % predicted: 159.7% vs. 129%, p<0.01), and shorter 6-minute walk distance (367.5 m vs. 390 m, p=0.02).Conclusion: SAD is present across all severities of COPD. The prevalence of SAD increases with disease severity. SAD is associated with poor lung function and higher symptom burden. Severe SAD is indicated by the presence of EFLT.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"165-175"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990611/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association between Antacid Exposure and Risk of Interstitial Lung Diseases. 抗酸剂接触与间质性肺病风险之间的关系

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.4046/trd.2023.0093

Soohyun Bae, Gjustina Loloci, Dong Yoon Lee, Hye Jin Jang, Jihyeon Jeong, Won-Il Choi

{"title":"Association between Antacid Exposure and Risk of Interstitial Lung Diseases.","authors":"Soohyun Bae, Gjustina Loloci, Dong Yoon Lee, Hye Jin Jang, Jihyeon Jeong, Won-Il Choi","doi":"10.4046/trd.2023.0093","DOIUrl":"10.4046/trd.2023.0093","url":null,"abstract":"Background: The mechanisms leading to lung fibrosis are still under investigation. This study aimed to demonstrate whether antacids could prevent the development of interstitial lung disease (ILD).Methods: This population-based longitudinal cohort study was conducted between January 2006 and December 2010 in South Korea. Eligible subjects were ≥40 years of age, exposed to proton pump inhibitors (PPI)±histamine-2 receptor antagonists (H-2 blockers) or H-2 blockers only, and had no history of ILD between 2004 and 2005. Exposure to antacids was defined as the administration of either PPI or H-2 receptor antagonists for >14 days, whereas underexposure was defined as antacid treatment administered for less than 14 days. Newly developed ILDs, including idiopathic pulmonary fibrosis (IPF), were counted during the 5-year observation period. The association between antacid exposure and ILD development was evaluated using adjusted Cox regression models with variables, such as age, sex, smoking history, and comorbidities.Results: The incidence rates of ILD with/without antacid use were 43.2 and 33.8/100,000 person-years, respectively and those of IPF were 14.9 and 22.9/100,000 person-years, respectively. In multivariable analysis, exposure to antacid before the diagnosis of ILD was independently associated with a reduced development of ILD (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.45 to 0.71; p<0.001), while antacid exposure was not associated with development of IPF (HR, 0.88; 95% CI, 0.72 to 1.09; p=0.06).Conclusion: Antacid exposure may be independently associated with a decreased risk of ILD development.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"185-193"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial Lung Abnormality in Asian Population. 亚洲人的肺间质异常。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-19 DOI: 10.4046/trd.2023.0117

Gong Yong Jin

{"title":"Interstitial Lung Abnormality in Asian Population.","authors":"Gong Yong Jin","doi":"10.4046/trd.2023.0117","DOIUrl":"10.4046/trd.2023.0117","url":null,"abstract":"Interstitial lung abnormalities (ILAs) are radiologic abnormalities found incidentally on chest computed tomography (CT) that can be show a wide range of diseases, from subclinical lung fibrosis to early pulmonary fibrosis including definitive usual interstitial pneumonia. To clear up confusion about ILA, the Fleischner society published a position paper on the definition, clinical symptoms, increased mortality, radiologic progression, and management of ILAs based on several Western cohorts and articles. Recently, studies on long-term outcome, risk factors, and quantification of ILA to address the confusion have been published in Asia. The incidence of ILA was 7% to 10% for Westerners, while the prevalence of ILA was about 4% for Asians. ILA is closely related to various respiratory symptoms or increased rate of treatment-related complication in lung cancer. There is little difference between Westerners and Asians regarding the clinical importance of ILA. Although the role of quantitative CT as a screening tool for ILA requires further validation and standardized imaging protocols, using a threshold of 5% in at least one zone demonstrated 67.6% sensitivity, 93.3% specificity, and 90.5% accuracy, and a 1.8% area threshold showed 100% sensitivity and 99% specificity in South Korea. Based on the position paper released by the Fleischner society, I would like to report how much ILA occurs in the Asian population, what the prognosis is, and review what management strategies should be pursued in the future.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"134-144"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138809301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factors Associated with the Discrepancy between Exercise Capacity and Airflow Limitation in Patients with Chronic Obstructive Pulmonary Disease. 慢性阻塞性肺病患者运动能力与气流限制之间差异的相关因素。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-01-16 DOI: 10.4046/trd.2023.0068

Tae Hoon Kim, I Re Heo, Na Young Kim, Joo Hun Park, Hee-Young Yoon, Ji Ye Jung, Seung Won Ra, Ki-Suck Jung, Kwang Ha Yoo, Ho Cheol Kim

{"title":"Factors Associated with the Discrepancy between Exercise Capacity and Airflow Limitation in Patients with Chronic Obstructive Pulmonary Disease.","authors":"Tae Hoon Kim, I Re Heo, Na Young Kim, Joo Hun Park, Hee-Young Yoon, Ji Ye Jung, Seung Won Ra, Ki-Suck Jung, Kwang Ha Yoo, Ho Cheol Kim","doi":"10.4046/trd.2023.0068","DOIUrl":"10.4046/trd.2023.0068","url":null,"abstract":"Background: Exercise capacity is associated with lung function decline in chronic obstructive pulmonary disease (COPD) patients, but a discrepancy between exercise capacity and airflow limitation exists. This study aimed to explore factors contributing to this discrepancy in COPD patients.Methods: Data for this prospective study were obtained from the Korean COPD Subgroup Study. The exercise capacity and airflow limitation were assessed using the 6-minute walk distance (6-MWD; m) and forced expiratory volume in 1 second (FEV1). Participants were divided into four groups: FEV1 >50%+6-MWD >350, FEV1 >50%+6- MWD ≤350, FEV1 ≤50%+6-MWD >350, and FEV1 ≤50%+6-MWD ≤350 and their clinical characteristics were compared.Results: A total of 883 patients (male:female, 822:61; mean age, 68.3±7.97 years) were enrolled. Among 591 patients with FEV1 >50%, 242 were in the 6-MWD ≤350 group, and among 292 patients with FEV1 ≤50%, 185 were in the 6-MWD >350 group. The multiple regression analyses revealed that male sex (odds ratio [OR], 8.779; 95% confidence interval [CI], 1.539 to 50.087; p=0.014), current smoking status (OR, 0.355; 95% CI, 0.178 to 0.709; p=0.003), and hemoglobin levels (OR, 1.332; 95% CI, 1.077 to 1.648; p=0.008) were significantly associated with discrepancies in exercise capacity and airflow limitation in patients with FEV1 >50%. Meanwhile, in patients with FEV1 ≤50%, diffusion capacity of carbon monoxide (OR, 0.945; 95% CI, 0.912 to 0.979; p=0.002) was significantly associated with discrepancies between exercise capacity and airflow limitation.Conclusion: The exercise capacity of COPD patients may be influenced by factors other than airflow limitation, so these aspects should be considered when assessing and treating patients.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"155-164"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139472024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Functional Aspects of the Obesity Paradox in Patients with Severe Coronavirus Disease-2019: A Retrospective, Multicenter Study. 严重冠状病毒病-2019 患者肥胖悖论的功能方面：一项回顾性多中心研究。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-12-26 DOI: 10.4046/trd.2023.0126

Jeongsu Kim, Jin Ho Jang, Kipoong Kim, Sunghoon Park, Su Hwan Lee, Onyu Park, Tae Hwa Kim, Hye Ju Yeo, Woo Hyun Cho

{"title":"Functional Aspects of the Obesity Paradox in Patients with Severe Coronavirus Disease-2019: A Retrospective, Multicenter Study.","authors":"Jeongsu Kim, Jin Ho Jang, Kipoong Kim, Sunghoon Park, Su Hwan Lee, Onyu Park, Tae Hwa Kim, Hye Ju Yeo, Woo Hyun Cho","doi":"10.4046/trd.2023.0126","DOIUrl":"10.4046/trd.2023.0126","url":null,"abstract":"Background: Results of studies investigating the association between body mass index (BMI) and mortality in patients with coronavirus disease-2019 (COVID-19) have been conflicting.Methods: This multicenter, retrospective observational study, conducted between January 2020 and August 2021, evaluated the impact of obesity on outcomes in patients with severe COVID-19 in a Korean national cohort. A total of 1,114 patients were enrolled from 22 tertiary referral hospitals or university-affiliated hospitals, of whom 1,099 were included in the analysis, excluding 15 with unavailable height and weight information. The effect(s) of BMI on patients with severe COVID-19 were analyzed.Results: According to the World Health Organization BMI classification, 59 patients were underweight, 541 were normal, 389 were overweight, and 110 were obese. The overall 28-day mortality rate was 15.3%, and there was no significant difference according to BMI. Univariate Cox analysis revealed that BMI was associated with 28-day mortality (hazard ratio, 0.96; p=0.045), but not in the multivariate analysis. Additionally, patients were divided into two groups based on BMI ≥25 kg/m2 and underwent propensity score matching analysis, in which the two groups exhibited no significant difference in mortality at 28 days. The median (interquartile range) clinical frailty scale score at discharge was higher in nonobese patients (3 [3 to 5] vs. 4 [3 to 6], p<0.001). The proportion of frail patients at discharge was significantly higher in the nonobese group (28.1% vs. 46.8%, p<0.001).Conclusion: The obesity paradox was not evident in this cohort of patients with severe COVID-19. However, functional outcomes at discharge were better in the obese group.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"176-184"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990606/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139040562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of Single Port Rigid Thoracoscopy in Undiagnosed Pleural Effusion. 单孔硬质胸腔镜在未确诊胸腔积液中的作用。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2024-02-02 DOI: 10.4046/trd.2023.0102

Jagdish Rawat, Anil Kumar, Parul Mrigpuri, Dev Singh Jangpangi, Abhay Pratap Singh, Ritisha Bhatt

{"title":"Role of Single Port Rigid Thoracoscopy in Undiagnosed Pleural Effusion.","authors":"Jagdish Rawat, Anil Kumar, Parul Mrigpuri, Dev Singh Jangpangi, Abhay Pratap Singh, Ritisha Bhatt","doi":"10.4046/trd.2023.0102","DOIUrl":"10.4046/trd.2023.0102","url":null,"abstract":"Background: In recent years, medical thoracoscopy has been well established to play an important role in undiagnosed pleural effusion; however, this procedure is underutilized due to limited availability of the instruments it requires. This study analysed the outcome of single port rigid thoracoscopy in patients with undiagnosed pleural effusions.Methods: This study retrospectively analysed the outcomes of all patients with undiagnosed pleural effusion presenting to our centre between 2016 to 2020 who underwent single port rigid medical thoracoscopy as a diagnostic procedure.Results: In total, 92 patients underwent single port rigid medical thoracoscopy. The most common presenting symptom was shortness of breath. A majority of the patients had lymphocytic exudative pleural effusion. The average biopsy sample size was 18 mm, and no major complication was reported in any of the patients.Conclusion: Single port rigid thoracoscopy is a safe and well-tolerated procedure that yields a biopsy of a larger size with high diagnostic yield. Moreover, the low cost of the instruments required by this procedure makes it particularly suited for use in developing countries.","PeriodicalId":23368,"journal":{"name":"Tuberculosis and Respiratory Diseases","volume":" ","pages":"194-199"},"PeriodicalIF":2.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10990617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Outcomes of Amikacin Liposome Inhalation Suspension for Refractory Mycobacterium avium Complex Pulmonary Disease. 阿米卡星脂质体吸入悬浮液治疗难治性禽分枝杆菌复合型肺部疾病的真实疗效。

IF 2.9

Tuberculosis and Respiratory Diseases Pub Date : 2024-04-01 Epub Date: 2023-09-20 DOI: 10.4046/trd.2023.0120

Bo-Guen Kim, Sae Rom Kim, Byung Woo Jhun

引用次数: 0